Ul­tragenyx adds new CMO with in­ter­nal pro­mo­tion; Au­to­lus CFO to leave for Mor­phoSys — but not quite yet

As Ul­tragenyx looks to use the ac­cel­er­at­ed ap­proval path­way for an in­creas­ing num­ber of rare dis­ease drugs, the com­pa­ny has pro­mot­ed Er­ic Crombez to EVP and chief med­ical of­fi­cer, ef­fec­tive May 1.

Crombez, who pre­vi­ous­ly served as CMO for gene ther­a­py and in­born er­rors of me­tab­o­lism, joined Ul­tragenyx fol­low­ing its $138 mil­lion ac­qui­si­tion of Di­men­sion Ther­a­peu­tics in No­vem­ber 2017. Since Jan­u­ary 2020, he’s al­so served in a non-vot­ing role as in­dus­try rep­re­sen­ta­tive on the FDA’s Cel­lu­lar, Tis­sue, and Gene Ther­a­pies Ad­vi­so­ry Com­mit­tee.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.